

Chair(s): Keith Kerr, GB; Pedro Romero, CH

- 13:56 - 14:16 **Back to the basics**
P. Romero, Epalinges, CH
- 14:16 - 14:36 **Biomarkers**
K. Kerr, Aberdeen, GB
- 14:36 - 14:56 **Immune checkpoints: Do we really know how they work?**
J. Haanen, Amsterdam, NL
- 14:56 - 15:16 **How to combine with I-O drugs**
I. Melero, Pamplona, ES
- 15:16 - 15:26 **General discussion / Q&A**

13.12.2018

11:15 - 12:45 **Type: Educational session** **Room A**
Title: Introduction to immunotherapy in cancer
Chair(s): Pedro Romero, CH; Keith Kerr, GB

- 11:15 - 11:35 **Back to the basics**
P. Romero, Epalinges, CH
- 11:35 - 11:55 **Biomarkers**
K. Kerr, Aberdeen, GB
- 11:55 - 12:15 **Immune checkpoints: Do we really know how they work?**
J. Haanen, Amsterdam, NL
- 12:15 - 12:35 **How to combine with I-O drugs**
J. Haanen, Amsterdam, NL
- 12:35 - 12:45 **General discussion / Q&A**

12:45 - 13:30 **Type: Break** **Foyer**
Title: Welcome reception

13:30 - 13:45 **Type: Educational session** **Room A**
Title: Opening and welcome

13:30 - 13:45 **Welcome to the Congress**
G. Coukos¹, J. Haanen²; ¹Epalinges, CH, ²Amsterdam, NL

13:45 - 14:15 **Type: Keynote Lecture** **Room A**
Title: Opening keynote - Award lecture
Chair(s): George Coukos, CH; John Haanen, NL

13:45 - 14:15 **Combination immunotherapy of cancers caused by high-risk human papillomavirus**
C. Melief, Leiden, NL

14:30 - 16:00 **Type: Educational session** **Room A**
Title: Adoptive T cell therapy
Chair(s): George Coukos, CH; John Haanen, NL

14:30 - 14:50 **TCR based adoptive immunotherapy**
T. Blankenstein, Berlin, DE

14:50 - 15:10 **Long term effects of CD19 CAR based adoptive therapy**
M. Sadelain, New York, US

15:10 - 15:30 **New directions in CAR therapy**
F. Thistlethwaite, Manchester, GB

15:30 - 15:50 **Adoptive immunotherapy for solid malignancies: Current status, paths forward**
C. Klebanoff, New York, US

15:50 - 16:00 **General discussion / Q&A**

16:00 - 16:30 **Type: Break** **Foyer**
Title: Coffee break

16:30 - 18:00 **Type: Educational session** **Room A**
Title: Biomarkers (host related)
 Chair(s): Naiyer Rizvi, US; Pedro Romero, CH

16:30 - 16:50 **Mining the microbiomes for biomarkers in cancer immune therapy**
J. Wargo, Houston, US

16:50 - 17:10 **High-dimensional profiling of human antigen-specific T cells: Asking T cells about what they “see” in cancer**
E. Newell, Singapore, SG

17:10 - 17:30 **Immune cells in the tumour microenvironment**
J. De Vries, Nijmegen, NL

17:30 - 17:50 **Biomarker development in the lung cancer combination therapy space**
N. Rizvi, New York, NY/US

17:50 - 18:00 **General discussion / Q&A**

16:30 - 18:00 **Type: Educational session** **Room C**
Title: Combinations with other modalities
 Chair(s): Charles Drake, US; Dirk De Ruyscher, NL

16:30 - 16:50 **Standard chemotherapy: A synergy with I/O?**
M. Reck, Grosshansdorf, DE

16:50 - 17:10 **Radiotherapy to boost the immune system**
D. De Ruyscher, Maastricht, NL

17:10 - 17:30 **Vaccination strategies in combination with other I/O**
M. van den Heuvel, Malden, NL

17:30 - 17:50 **I-O and modulators of the tumour micro-environment**
G. Coukos, Epalinges, CH

17:50 - 18:00 **General discussion / Q&A**

18:15 - 19:00 **Type: Proffered Paper session** **Room A**
Title: Proffered Paper session I
Chair(s): John Haanen, NL; Solange Peters, CH

18:15 - 18:30 **LBA5 - Efficacy and safety of nivolumab (nivo) monotherapy versus chemotherapy (chemo) in recurrent small cell lung cancer (SCLC): Results from CheckMate 331**

M. Reck¹, D. Vicente², T. Ciuleanu³, S. Gettinger⁴, S. Peters⁵, L. Horn⁶, C. Audigier-Valette⁷, N. Pardo⁸, O. Juan-Vidal⁹, Y. Cheng¹⁰, H. Zhang¹¹, M. Shi¹², J. Wolf¹³, S. Antonia¹⁴, K. Nakagawa¹⁵, G. Selvaggi¹⁶, C. Baudelet¹⁶, H. Chang¹⁶, D. Spigel¹⁷; ¹Grosshansdorf, DE, ²Sevilla, ES, ³Cluj-Napoca, RO, ⁴New Haven, CT/US, ⁵Lausanne, CH, ⁶Nashville, TN/US, ⁷Toulon, FR, ⁸Barcelona, ES, ⁹Valencia, ES, ¹⁰Changchun, CN, ¹¹Xi'an, CN, ¹²Nanjing, CN, ¹³Koeln, DE, ¹⁴Tampa, FL/US, ¹⁵Osaka, JP, ¹⁶Princeton, NJ/US, ¹⁷Nashville, US

18:30 - 18:45 **LBA6 - Durvalumab with or without tremelimumab vs platinum-based chemotherapy as first-line treatment for metastatic non-small cell lung cancer: MYSTIC**

N. Rizvi¹, B. Chul Cho², N. Reinmuth³, K.H. Lee⁴, M.-J. Ahn², A. Luft⁵, M. van den Heuvel⁶, M. Cobo⁷, A. Smolin⁸, D. Vicente⁹, V. Moiseyenko¹⁰, S. Antonia¹¹, S. Le Moulec¹², G. Robinet¹³, R. Natale¹⁴, K. Nakagawa¹⁵, L. Zhao¹⁶, P. Stockman¹⁷, V. Chand¹⁶, S. Peters¹⁸; ¹New York, NY/US, ²Seoul, KR, ³Gauting, DE, ⁴Cheongju, KR, ⁵Saint Petersburg, RU, ⁶Malden, NL, ⁷Málaga, ES, ⁸Moscow, RU, ⁹Sevilla, ES, ¹⁰Saint-Petersburg, RU, ¹¹Tampa, FL/US, ¹²Paris, CEDEX 5/FR, ¹³Brest, Cedex 2/FR, ¹⁴Los Angeles, CA/US, ¹⁵Osaka, JP, ¹⁶Gaithersburg, US, ¹⁷Macclesfield, GB, ¹⁸Lausanne, CH

18:45 - 19:00 **Invited Discussant LBA5 and LBA6**
E. Smit, Amsterdam, NL

14.12.2018

09:00 - 10:30 **Type: Proffered Paper session** **Room A**
Title: Proffered Paper session II
Chair(s): George Coukos, CH; John Haanen, NL

09:00 - 09:15 **310 - T cell therapy with EBV-specific cytotoxic T-lymphocytes for patients with nasopharyngeal carcinoma**

P. Pedrazzoli, P. Comoli, S. Secondino, A. Gurrado, A. Pagani, M. Zecca; Pavia, IT

09:15 - 09:30 **320 - Successful use of interferon-alpha and adoptive T cell therapy for metastatic melanoma patients failing other treatment options**

M. van der Kooij¹, E.M.E. Verdegaal¹, M. Visser¹, L. De Bruin¹, C.E. Van der Minne¹, S. Santegoets¹, M. Welters¹, J. Haanen², E. Kapiteijn¹, S. van der Burg¹; ¹Leiden, NL, ²Amsterdam, NL

09:30 - 09:45 **680 - Ligand-inducible, prostate stem cell antigen (PSCA)-directed GoCAR-T cells in advanced solid tumors: Preliminary results from a dose escalation study**

C. Becerra¹, P. Hoof², S. Paulson², G. Manji³, O. Gardner⁴, A. Malankar⁵, J. Shaw⁴, D. Blass⁴, B. Ballard⁴, X. Yi⁴, M. Anumula⁴, A. Foster⁴, J. Senesac⁴, P. Woodard⁴; ¹Dallas, US, ²Dallas, TX/US, ³New York City, US, ⁴Houston, TX/US, ⁵Houston, US

09:45 - 10:00 **Invited Discussant 310, 320 and 680**

G. Coukos, Epalinges, CH

10:00 - 10:15 **690 - A small molecule human PD-1/PD-L1 inhibitor promotes T cell immune activation and reduces tumor growth in a preclinical model**

M. Vilalta Colomer¹, S. Punna¹, S. Li², V. Malathong², C. Lange², D. McMurtrie², J. Yang², H. Roth², J. McMahan², J. Campbell³, L. Ertl², R. Ong², Y. Wang², N. Zhao², S. Yau², T. Dang², P. Zhang², T. Schall², R. Singh²; ¹Mountain View, US, ²Mountain View, CA/US, ³Mountain View, Ca, US

10:15 - 10:30 **Invited Discussant 690**

J. Haanen, Amsterdam, NL

09:00 - 10:30 **Type: Educational session** **Room C**
Title: Management of side effects
 Chair(s): Reinhard Dummer, CH; Josep Taberero, ES

09:00 - 09:20 **Handling of GI toxicity from immune checkpoint inhibitors**
F. Carbonnel, Le Kremlin Bicetre, FR

09:20 - 09:40 **Genetic host factors predictive of toxicity from immune checkpoint inhibitors**
T. Kirchhoff, New York, US

09:40 - 10:00 **Requirements for safely administering combination of ipilimumab + nivolumab**
H. Kluger, New Haven, US

10:00 - 10:20 **How rare are rare immune related Aes?**
R. Dummer, Zurich, CH

10:20 - 10:30 **General discussion / Q&A**

10:30 - 11:00 **Type: Break** **Foyer**
Title: Coffee break

11:00 - 12:30 **Type: Educational session** **Room A**
Title: Innovative technological development
 Chair(s): Aurelien Marabelle, FR; George Coukos, CH

11:00 - 11:20 **Conditionally active antibodies for immunotherapy**
N. Lonberg, Redwood City, California/US

11:20 - 11:40 **Generation of bio-specific antibodies with several targets**
M. Bacac, Schlieren, CH

11:40 - 12:00 **ADU-S100 (MIW815), a first-in-class STING agonist**
A. Van Elsas, Oss, NL

12:00 - 12:20 **RNA vaccines**
Ö. Türeci, Mainz, DE

12:20 - 12:30 **General discussion / Q&A**

11:00 - 12:30 **Type: Educational session** **Room C**
Title: Biomarkers (tumour related)
 Chair(s): Sergio Quezada, GB; Christian Blank, NL

- 11:00 - 11:20 **Understanding the mechanisms to develop combinations of immunoregulatory agents with radiotherapy**
E. Cheadle, Manchester, GB
- 11:20 - 11:40 **Genomics response assessment**
C. Blank, Amsterdam, NL
- 11:40 - 12:00 **Engineered antibodies for imaging immune cell subsets**
A. Wu, Los Angeles, US
- 12:00 - 12:20 **Tracking T cell evolution in cancer**
S. Quezada, London, London/GB
- 12:20 - 12:30 **General discussion / Q&A**

12:30 - 13:00 **Type: Poster Display session** **Room B**
Title: Poster Display session

- 12:30 - 12:30 **Biomarker Development**
- 12:30 - 12:30 **3P - Dissecting the spatial heterogeneity of single CTCs reveals immune evasion through MAX regulated CCL5 overexpression in hepatocellular carcinoma**
Y. Sun, X.-R. Yang, J. Fan; Shanghai, CN
- 12:30 - 12:30 **4P - Prospective study of circulating tumor cells in long survivors of immunotherapy**
M. Brenes Fernández¹, A. Garcia Grande¹, F. Franco¹, M.J. Coronado¹, V. Calvo¹, L. Gutierrez Sanz¹, J. Sanchez¹, M. Torrente Regidor¹, B. Núñez¹, R. Gómez Bravo¹, M. Provencio Pulla²; ¹Madrid, ES, ²Majadahonda, Madrid/ES
- 12:30 - 12:30 **5P - Baseline CRP predicts severe immune related adverse events**
R. Verheijden, K. Suijkerbuijk; Utrecht, NL
- 12:30 - 12:30 **6P - Predictive score using clinical and blood biomarkers in advanced non-small cell lung cancer (aNSCLC) patients treated with immunotherapy**
A. Prelaj¹, S.E. Rebuzzi², P. Pizzutilo³, M. Montrone³, F. Pesola³, V. Longo³, V. Lapadula³, F. Cassano³, P. Petrillo³, D. Bafunno³, N. Varesano³, V. Lamorgese³, A. Mastrandrea³, D. Ricci³, A. Catino³, G. Domenico³; ¹Roma, IT, ²Genova, IT, ³Bari, IT

- 12:30 - 12:30 **7P - Monocyte-to-lymphocyte ratio (MLR) and LDH level in metastatic colorectal cancer (mCRC) patients (pts)**
D. Basile¹, L. Gerratana², C. Corvaja², G. Pelizzari², S.K. Garattini², C. Lisanti², M. Bartoletti², L. Bortot², V. Fanotto², E. Ongaro², F. Cortiula², A. Parnofiello², M. Vitale², L. Da Ros¹, P. Di Nardo¹, E. Torrasi¹, M. Guardascione³, G. Miolo¹, A. Buonadonna¹, F. Puglisi¹; ¹Aviano, IT, ²Udine, IT, ³Aviano, Pordenone/IT
- 12:30 - 12:30 **8P - Anti-PD1 therapy increases peripheral blood NKT cells and chemokines in metastatic melanoma patients**
H. Hakanen, M. Hernberg, S. Mäkelä, B. Yadav, O. Brück, S. Juteau, L. Kohtamäki, M. Ilander, S. Mustjoki, A. Kreutzman; Helsinki, FI
- 12:30 - 12:30 **9P - Identification of serum microRNAs predicting the response to nivolumab in patients with advanced gastric cancer**
T. Miyamoto¹, K. Kato², J. Matsuzaki², S. Takizawa², K. Sudo², H. Shoji², S. Iwasa², Y. Honma², A. Takashima², N. Okita², H. Sakamoto², N. Boku³, O. Takahiro²; ¹Chuo-Ku, JP, ²Tokyo, JP, ³Kawasaki, JP
- 12:30 - 12:30 **10P - Clinical and laboratory predictors of immune checkpoint inhibitor efficacy in non-small cell lung cancer**
P. Christopoulos, J. Kohlhäufel, F. Bozorgmehr, J. Kuon, M. Schneider, O. Neumann, S. Liersch, C. Heussel, H. Winter, F. Herth, S. Rieken, T. Muley, M. Meister, H. Bischoff, F. Lasitschka, A. Stenzinger, M. Thomas; Heidelberg, DE
- 12:30 - 12:30 **11P - A SNP germinal signature for predicting checkpoint inhibitor treatment outcome**
G. Milano¹, S. Refae¹, J. Gal¹, N. Ebran¹, J. Otto¹, S. Shell², R. Everts², E. Chamorey¹, E. Saada-Bouazid¹; ¹Nice, FR, ²San Diego, US
- 12:30 - 12:30 **12P - MSI status plus immunoscore to select metastatic colorectal cancer patients for immunotherapies**
J. Galon¹, B. Mlecnik¹, F. Hermitte², F. Marliot¹, C. Bifulco³, A. Lugli⁴, I. Nagtegaal⁵, A. Hartmann⁶, M. van den Eynde⁷, M. Roehrl⁸, P. Ohashi⁹, E. Zavadova¹⁰, T. Torigoe¹¹, P. Patel¹², Y. Wang¹³, Y. Kawakami¹⁴, F. Marincola¹⁵, P. Ascierto¹⁶, B. Fox¹⁷, F. Pagès¹; ¹Paris, FR, ²Marseille, FR, ³Portland, OR/US, ⁴Bern, CH, ⁵Nijmegen, NL, ⁶Erlangen, DE, ⁷Brussels, BE, ⁸New-York, AL/US, ⁹Toronto, ON/CA, ¹⁰Prague, 2/CZ, ¹¹Sapporo, JP, ¹²Ahmedabad, IN, ¹³Xian, CN, ¹⁴Tokyo, JP, ¹⁵Redwood City, CA/US, ¹⁶Napoli, IT, ¹⁷Portland, US
- 12:30 - 12:30 **13P - Correlative analysis of gene expression changes and PD-L1 immunoexpression in non-small cell lung cancer**
I. Guerreiro, D. Barros-Silva, P. Lopes, A.L. Cunha, J. Lobo, A. Rodrigues, M. Soares, L. Antunes, R. Henrique, C. Jerónimo; Porto, PT
- 12:30 - 12:30 **14P - Relation between IDH1 status, histologic grade, immune-cell infiltration and expression of immune-related genes in patients with gliomas**
S. Cabezas-Camarero, R. Pérez-Alfayate, I. Casado Fariñas, M. Sáiz-Pardo Sanz, I. Subhi-Issa, P. Pérez-Segura, V. García-Barberán; Madrid, ES

- 12:30 - 12:30 **15P - Using a multiplexed immunofluorescence assay to detect immunosuppressive cells and their mechanisms in the pancreatic tumor microenvironment**
A. Juncker-Jensen¹, J. Fang², R. Padmanabhan², E. Parnell², J. Kuo², Q. Au², E. Leones², F. Sahafi², M. Nagy², N. Hoe², J. William²; ¹Aliso Viejo, US, ²Aliso Viejo, CA/US
- 12:30 - 12:30 **16P - Analysis of immune checkpoint- and apoptosis-related lymphocyte markers expression and its association with the prevalence of regulatory lymphocyte populations in the establishment of microinvasive cervical carcinoma**
O. Kurmyshkina, T. Volkova; Petrozavodsk, RU
- 12:30 - 12:30 **17P - The prognostic significance of androgen receptor phosphorylation and the immune infiltrate in prostate cancer**
H.W.G. Gan, M. McAllister, V. Constancio, S. Payne, M. Underwood, H. Leung, J. Edwards; Glasgow, GB
- 12:30 - 12:30 **18P - Dissecting the antitumor immune response upon PARP inhibition in homologous recombination repair (HRR)-deficient tumors**
B. Pellegrino¹, A. Llop-Guevara², C. Cruz², M. Castroviejo², A. Cedro-Tanda³, R. Fasani², P. Nuciforo², A. Gros², J. Balmaña², M. O'Connor⁴, V. Serra Elizalde²; ¹Parma, IT, ²Barcelona, ES, ³Ciudad De Mexico, MX, ⁴Cambridge, GB
- 12:30 - 12:30 **19P - Signs of immunosenescence in patients diagnosed with non-small cell lung cancer**
T. Soria Comes, V. Palomar-Abril, M. Martin Ureste, J.E. Marco Buades, M.J. Fernandez Llavador, J. Garcia Sanchez, M.D.C. Cancela Gomez, I. Maestu Maiques; Valencia, ES
- 12:30 - 12:30 **20P - Dynamic of systemic immunity and its impact on tumor recurrence after radiofrequency ablation of hepatocellular carcinoma**
P. Rochigneux¹, J.C. Nault², N. Ganne-Carrié², D. Olive³; ¹Marseille, CEDEX 9/FR, ²Bondy, FR, ³Marseille, FR
- 12:30 - 12:30 **21P - Baseline total metabolic tumor volume assessed by 18FDG-PET/CT predicts outcome in advanced melanoma patients treated with pembrolizumab**
G. Awada¹, I. Özdemir¹, J. Schwarze¹, E. Daeninck¹, O. Gondry¹, Y. Jansen¹, T. Seremet¹, M. Keyaerts¹, H. Everaert¹, B. Neyns²; ¹Brussels, BE, ²Jette, BE
- 12:30 - 12:30 **22P - PD-L1 microSPECT/CT imaging for longitudinal monitoring of PD-L1 expression in syngeneic and humanized mouse models for cancer**
S. Heskamp¹, S. Verhoeff¹, P. Wierstra¹, J. Molkenboer-Kuenen¹, G. Sandker¹, S. Thordardottir¹, D. Olive², J. Bussink¹, O. Boerman¹, H. Dolstra¹, E. Aarntzen¹, W. Hobo¹; ¹Nijmegen, NL, ²Marseille, FR
- 12:30 - 12:30 **23P - The effect of tumor derived HMBG1 on intra-tumoral B cells in esophageal squamous cell carcinoma**
D. Kwong, Y. Kam, X. Guan; Hong Kong, HK

- 12:30 - 12:30 **24P - Osteosarcoma cell intrinsic PD-L2 signals promote invasion and metastasis via the RhoA-ROCK-LIMK2 and autophagy pathways**
T. Ren, B. Zheng, W. Guo; Beijing, CN
- 12:30 - 12:30 **25P - Unsupervised analysis of the extent, organization and phenotype of tumor-infiltrating lymphocytes in breast cancer identifies two major clusters**
C. Solinas, F. Richard, S. Garaud, P. De Silva, A. de Wind, G. Van Den Eyden, C. Gu-Trantien, M. Langouo Fontsa, G. Noël, A. Boisson, C. Naveaux, H. Duvillier, L. Craciun, D. Larsimont, K. Willard-Gallo; Brussels, BE
- 12:30 - 12:30 **26P - Lymphotoxin alpha functional germline genetic variant: A future prognostic factor in colorectal cancer?**
M. Rocha¹, F. Pinheiro¹, B. Cardoso¹, M. Del Rio¹, A. Lojo Teira¹, M. Pires¹, E. Bastos¹, R. Ribeiro²; ¹Vila Real, PT, ²Porto, PT
- 12:30 - 12:30 **27P - Reliability of the detection of the mutation burden status by targeted next generation sequencing applying a large gene panel**
N. Pfarr¹, M. Boxberg¹, K. Riedmann¹, M. Jesinghaus¹, B. Konukiewitz¹, H. Glimm², P. Jost¹, S. Fröhling³, W. Weichert¹; ¹Munich, DE, ²Dresden, DE, ³Heidelberg, DE
- 12:30 - 12:30 **28TiP - CHECK'UP: A prospective cohort study to identify predictive factors of response and mechanisms of resistance to PD-1 and PD-L1 antagonists**
F. Penault-Llorca¹, C. Caux², S. Depil², C. Le Tourneau³, M. Pérol², C. Robert⁴, V. Soumelis³, D. Couch³, N. Isambert⁵, Y. Fernandez⁶, T. Filleron⁷, G. Vassal⁴; ¹Clermont-Ferrand, FR, ²Lyon, FR, ³Paris, FR, ⁴Villejuif, FR, ⁵Dijon, Cedex/FR, ⁶Vandoeuvre-Lès-nancy, FR, ⁷Toulouse, FR
- 12:30 - 12:30 **29TiP - A translational study to discover novel host-related immune-biomarkers for nivolumab (Nivo) in advanced gastric cancer (GC): JACCRO GC-08 (DELIVER trial)**
Y. Sunakawa¹, K. Muro², T. Nakajima³, H. Kawakami⁴, E. Inoue³, R. Matoba⁵, Y. Sato⁵, W. Ichikawa⁶, M. Fujii⁵; ¹Kanagawa, JP, ²Nagoya, Aichi/JP, ³Kawasaki, JP, ⁴Osaka, JP, ⁵Tokyo, JP, ⁶Yokohama, JP
- 12:30 - 12:30 **30TiP - Predictive markers of immune mediated adverse events and of treatment response in patients treated with durvalumab monotherapy or in combination with tremelimumab (IOPREDI study)**
A. Marabelle¹, F. Ghiringhelli², M. Ayyoub³, E. Tartour⁴, O. Adotevi⁵, Y. Loriot¹, O. Lambotte⁶, D. Cupissol⁷, D. Damotte⁴, J. Adam¹, M. Bonvalet¹, B. Petre Lazar⁴, M. Licour⁸, N. Chaput⁹; ¹Villejuif, FR, ²Dijon, FR, ³Toulouse, FR, ⁴Paris, FR, ⁵Besançon, CEDEX/FR, ⁶Le Kremlin Bicetre, FR, ⁷Montpellier, CEDEX 5/FR, ⁸Courbevoie, FR, ⁹Villejuif, CEDEX/FR
- 12:30 - 12:30 **Cell therapy**

- 12:30 - 12:30 **35P - Anti-human CD117 CAR T-cells efficiently eliminate hematopoietic stem and CD117-positive AML cells**
R. Myburgh¹, J. Kiefer², N. Russkamp¹, A. Simonis¹, S. Pfister¹, C. Magnani¹, M. Wilk¹, A. Müller¹, M. van den Broek¹, B. Becher², D. Neri², M. Manz¹; ¹Zurich, CH, ²Zürich, CH
- 12:30 - 12:30 **36P - CAR-modified natural killer cell line expressing CD47/SIRPa blockers as a combined approach for solid cancer therapy**
A. Chikaev, A. Gorchakov, S. Kulemzin, T. Belovezhets, D. Matvienko, O. Volkova, A. Taranin; Novosibirsk, RU
- 12:30 - 12:30 **37P - Pooling signaling and costimulatory domains in a flexible CARpool design**
L. Springuel¹, J. Bolsée², A. Velghe², S. Agaugué², D. Gilham²; ¹Mont Saint Guibert, BE, ²Mon-Saint-guibert, BE
- 12:30 - 12:30 **38P - SQZing cells to rapidly generate antigen presenting cells (APC) for solid tumor immune therapies with efficient, scalable manufacturing**
S. Loughhead¹, M. Booty², K. Hlavaty², A. Vicente-Suarez², K. Blagovic², M. Myint¹, B. Stokes², D. Yasar², H. Bernstein², A. Sharei²; ¹Watertown, US, ²Watertown, MA/US
- 12:30 - 12:30 **39P - A comparative study elucidating the substantial functional defects of electroporated T cells relative to a mechanical SQZ-based approach**
J. Hanson, J. Cole, L. Cassereau, J. Bugge, T. Ditommaso, J. Gilbert, H. Bernstein, A. Sharei; Watertown, US
- 12:30 - 12:30 **40P - Interest and potential of genetically engineered cord blood derived T cells for cancer immunotherapy**
C. Marton¹, P. Mercier-Letondal¹, M. Deschamps¹, C. Ferrand¹, O. Adotevi², C. Borg², J. Galaine¹, Y. Godet¹; ¹Besançon, FR, ²Besançon, CEDEX/FR
- 12:30 - 12:30 **41P - Impact of different GMP media in the production of dendritic cells for next-generation cancer immunotherapy: Functional and metabolic characterization**
J. Calmeiro¹, M. Carrascal², C. Gomes¹, A. Falcão¹, J. Serra², M. Cruz¹, B. Neves³; ¹Coimbra, PT, ²Sintra, PT, ³Aveiro, PT
- 12:30 - 12:30 **42P - A phase I clinical trial on intratumoral administration of autologous CD1c (BDCA-1)+ myeloid dendritic cells (myDC) in combination with ipilimumab (IPI) and avelumab (AVE) plus intravenous low-dose nivolumab (NIVO) in patients with advanced solid tumors**
J. Schwarze¹, G. Awada², I. Van Riet², B. Neyns²; ¹Brussels, BE, ²Jette, BE
- 12:30 - 12:30 **43P - Glioblastoma multiforme cells are sensitive to lysis mediated by killer dendritic cells via granule-dependent and death receptor-dependent mechanisms of cytotoxicity**
T. Tyrinova, O. Leplina, S. Mishinov, M. Tikhonova, A. Kalinovskiy, S. Chernov, V. Stupak, A. Ostanin, E. Chernykh; Novosibirsk, RU

- 12:30 - 12:30 **44P - PD-L1 blockade during ex vivo expansion of virus-specific T cells for the treatment of infections after allogeneic hematopoietic stem cell transplantation modulates the phenotype and functional activity of T cells**
M. Merhi, M. Jalis, S. Sivaraman, V. Inchakalody, A. Raza, M. Bakr, G. Pittari, S. Uddin, A. Knuth, S. Dermime; Doha, QA
- 12:30 - 12:30 **45P - Effective treatment of nasopharyngeal carcinoma with autologous Epstein-Barr Virus and oncogene-targeted cytotoxic T lymphocytes**
W. Xia, L. Guoying, Y. Xiang; Guangzhou, CN
- 12:30 - 12:30 **46P - Inflamed human oropharyngeal cancers with ongoing tumor-specific T cell responses comprise a different type of immune suppressive T cells**
S. Santegoets, C. Duurland, E. Jordanova, V. van Ham, I. Ehsan, M. Welters, S. van der Burg; Leiden, NL
- 12:30 - 12:30 **47P - An investigation into the effects of prior irradiation to the tumour mass on murine TIL expansion**
A. Azizi, E. Cheadle, A. Popple, T. Illidge; Manchester, GB
- 12:30 - 12:30 **48TiP - A phase II study of autologous tumor infiltrating lymphocytes (TIL; LN-144/LN-145) in patients with solid tumors**
J. Chesney¹, A. Cacovean², H. Li³, D. Barton³, M. Fardis³; ¹Louisville, KY/US, ²San Carlos, US, ³San Carlos, CA/US
- 12:30 - 12:30 **Clinical practice (including toxicities)**
- 12:30 - 12:30 **52P - Differential effects of corticosteroids and anti-TNF on tumor-specific immune responses: Implications for the management of irAEs**
A. Draghi¹, T. Borch¹, H.D. Radic¹, C. Chamberlain², A. Gokuldass¹, I.-M. Svane¹, M. Donia¹; ¹Herlev, DK, ²Copenhagen, DK
- 12:30 - 12:30 **53P - Immune-related adverse events correlate with clinical outcomes in non-small cell lung cancer (NSCLC) patients treated with nivolumab in the Italian expanded access programme**
E. Baldini¹, A. Lunghi², E. Cortesi³, D. Turci⁴, M. Garassino⁵, V. Stati⁶, A. Ardizzoni⁷, B. Ricciuti⁸, A. Frassoldati⁹, G. Romano¹⁰, A. Illiano¹¹, F. Verderame¹², G. Fasola¹³, P. Marchetti¹⁴, C. Pinto¹⁵, G. Carteni¹, V. Scotti¹⁶, C. Tibaldi¹⁷, L. Fioretto¹⁶, D. Giannarelli¹⁴; ¹Lucca, IT, ²Vallo Della Lucania, IT, ³Rome, IT, ⁴Ravenna, IT, ⁵Milan, IT, ⁶Roma, RM/IT, ⁷Bologna, IT, ⁸Perugia, (PG)/IT, ⁹Ferrara, IT, ¹⁰Lecce, IT, ¹¹Napoli, IT, ¹²Palermo, IT, ¹³Udine, IT, ¹⁴Roma, IT, ¹⁵Reggio Emilia, IT, ¹⁶Firenze, IT, ¹⁷Carrara, IT
- 12:30 - 12:30 **54P - Incidence of programmed cell death 1 inhibitor-related diarrhea in patients with advanced cancer: A systematic review and meta-analysis**
J.-D. Sui, Y. Wang, Y. Wan, Y.-Z. Wu; Chongqing, CN

- 12:30 - 12:30 **55P - Efficacy and safety of nintedanib and docetaxel in lung adenocarcinoma patients (pts) following treatment with immune checkpoint inhibitors (ICIs): First interim results of the ongoing non-interventional study VARGADO (NCT02392455)**
C. Grohe¹, W. Gleiber², S. Haas³, H. Mueller-Huesmann⁴, M. Schulze⁵, J. Atz⁶, R. Kaiser⁶; ¹Berlin, DE, ²Frankfurt, GE, ³Neumünster, DE, ⁴Paderborn, DE, ⁵Zittau, DE, ⁶Ingelheim Am Rhein, DE
- 12:30 - 12:30 **56P - Evaluating safety and efficacy of immune checkpoint inhibitors (ICI) in elderly patients (pts) for advanced cancer treatment: A retrospective study**
S. Brixius, F. Meiss, D. von Bubnoff, R. Zeiser, C. Waller, J. Duyster, J. Rawluk; Freiburg, DE
- 12:30 - 12:30 **57P - The efficacy and safety of rechallenge with an alternative immune checkpoint inhibitor in metastatic malignant melanoma**
A.A. Mohamed, S. Zhang, G. Faust; Leicester, GB
- 12:30 - 12:30 **58P - The unexpected challenges of immunotherapy**
A. Olsson-Brown¹, T. Guinan², M. McKay², S. Chow², R. Lord², M. Pirmohamed¹, J. Sacco²; ¹Liverpool, GB, ²Wirral, GB
- 12:30 - 12:30 **59P - Nivolumab treatment in patients with relapsed/refractory HIV-related lymphomas**
Y. Rogacheva¹, M. Popova², A. Nekrasova², I. Tsygankov², K. Lepik², L. Stelmah², I. Moiseev², S. Bondarenko², N. Mikhaylova³, V. Baykov², B. Afanasyev²; ¹Saint-Petersburg, RU, ²Saint Petersburg, RU, ³Санкт-Петербург, RU
- 12:30 - 12:30 **60P - Response rates with talimogene laherparepvec (T-VEC) monotherapy in patients (pts) with stage IIIB–IVM1c melanoma previously treated with checkpoint inhibitor (CPI) therapy: Retrospective analysis of two clinical trials**
H. Gogas¹, R. Gutzmer², J. Malvehy³, J. Mehnert⁴, K. Liu⁵, C. Pickett⁵, W. Snyder⁵, J. Chesney⁶; ¹Athens, GR, ²Hannover, DE, ³Barcelona, ES, ⁴New Brunswick, NJ/US, ⁵Thousand Oaks, CA/US, ⁶Louisville, KY/US
- 12:30 - 12:30 **61P - The real-world impact of cancer immunotherapy on the survival of patients with metastatic melanoma**
M. Donia¹, E. Ellebaek¹, T. Oellegaard², L. Duval², J. Aaby³, L. Hoejberg³, U. Koehler³, H. Schmidt⁴, L. Bastholt³, I.-M. Svane¹; ¹Herlev, DK, ²Aarhus, DK, ³Odense, DK, ⁴Aarhus C, DK
- 12:30 - 12:30 **62P - First-line systemic real-world treatment of patients with advanced/metastatic NSCLC in the UK**
M. Wang¹, P. Dhokia¹, S. Menon², B. Martindale³; ¹Uxbridge, GB, ²London, GB, ³Collegeville, US
- 12:30 - 12:30 **63P - A network meta-analysis of the frontline immune-checkpoint inhibitor-based regimens in advanced non-small cell lung cancer**

J. Kattan¹, E.E. Rassy¹, Z. Bakouny¹, T. Assi¹, N. Pavlidis²; ¹Beirut, LB, ²Ioannina, GR

12:30 - 12:30

64P - Post-progression evaluation of patients treated with nivolumab for advanced non-small cell lung cancer: A prospective cohort analysis

E. Quaquarini¹, L. Gervaso¹, F. Sottotetti¹, A. Bernardo¹, R. Palumbo¹, A. Gambaro², M. Frascaroli¹, B. Tagliaferri¹, C. Teragni¹, D. Presti¹, C. Porta¹; ¹Pavia, IT, ²Milano, IT

12:30 - 12:30

65P - A novel recombinant human anti-PD-1 monoclonal antibody GLS-010 in patients with advanced cancer: Result of a phase Ia clinical trial

L. Shen¹, J. Gong¹, Y. Xu¹, X. Zhang¹, Z. Peng¹, C. Qi¹, G. Li¹, H. Meng¹, Z. Liu¹, H. Wang¹, C. Chen², J. Li², Y. Zheng², J. Lee², Y. Zhang², Q. Zhang²; ¹Beijing, CN, ²Shanghai, CN

12:30 - 12:30

66P - Is the current healthcare system ready to treat all eligible patients using car t-cell therapies? An analysis of the NHL situation in France

T. Verrier¹, T. Sejourne², M. Rose², L. Mitrofan¹; ¹Paris, FR, ²Courbevoie, FR

12:30 - 12:30

67P - The predictive value of 18F-FDG PET/CT after ipilimumab for treatment response evaluation in metastatic melanoma patients

S. Vari¹, A. Annovazzi², R. Pasqualoni², R. Sciuto², D. Giannarelli², F. Cognetti², V. Ferraresi³; ¹London, GB, ²Rome, IT, ³Roma, IT

12:30 - 12:30

Therapeutic Development

12:30 - 12:30

71P - Phase I study of cemiplimab, a human monoclonal anti-PD-1, in patients with unresectable locally advanced or metastatic cutaneous squamous cell carcinoma (CSCC): Longer follow-up efficacy and safety data

T. Owonikoko¹, K. Papadopoulos², M. Johnson³, M. Gil Martín⁴, V. Moreno⁵, A. Salama⁶, E. Calvo⁵, N. Yee⁷, H. Safran⁸, R. Aljumaily⁹, D. Mahadevan¹⁰, J. Niu¹¹, K. Kal Mohan¹², J. Li¹³, E. Stankevich¹³, M. Mathias¹², I. Lowy¹⁴, M. Fury¹², H. Babiker¹⁵; ¹Atlanta, GA/US, ²San Antonio, TX/US, ³Nashville, TN/US, ⁴Barcelona, ES, ⁵Madrid, ES, ⁶Durham, NC/US, ⁷Hershey, PA/US, ⁸Providence, RI/US, ⁹Oklahoma City, OK/US, ¹⁰Memphis,, TN/US, ¹¹Gilbert, AZ/US, ¹²Tarrytown, NY/US, ¹³Basking Ridge, NJ/US, ¹⁴Tarrytown, US, ¹⁵Tucson, US

12:30 - 12:30

72P - Cemiplimab, a human monoclonal anti-PD-1, plus radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC): Results from a phase I expansion cohort (EC 2)

V. Moreno¹, M. Gil-Martin², M. Johnson³, R. Aljumaily⁴, P. Lopez Criado¹, D. Northfelt⁵, M. Crittenden⁶, S. Jabbour⁷, L. Rosen⁸, P. Garrido¹, A. Hervás Morón¹, P. Rietschel⁹, K. Mohan⁹, J. Li¹⁰, E. Stankevich¹⁰, M. Feng¹⁰, I. Lowy¹¹, M. Fury⁹; ¹Madrid, ES, ²Barcelona, ES, ³Nashville, TN/US, ⁴Oklahoma City, OK/US, ⁵Phoenix, AZ/US, ⁶Portland, OR/US, ⁷New Brunswick, NJ/US, ⁸Los Angeles, CA/US, ⁹Tarrytown, NY/US, ¹⁰Basking Ridge, NJ/US, ¹¹Tarrytown, US

- 12:30 - 12:30 **73P - Cemiplimab, a human monoclonal anti-PD-1, in patients (pts) with advanced or metastatic hepatocellular carcinoma (HCC): Data from an expansion cohort (EC) in a phase I study**
A.R. He¹, G. Weiss², G. Falchook³, N. Yee⁴, M. Gil-Martin⁵, S. Shahda⁶, V. Moreno⁷, I. Brana⁵, M. Crittenden⁸, S. Formenti⁹, R. Al-Rajabi¹⁰, K. Papadopoulos¹¹, M. Pishvaian¹, E. Stankevich¹², M. Feng¹², J. Li¹², M. Mathias¹³, G. Kroog¹³, I. Lowy¹⁴, M. Fury¹³; ¹Washington, US, ²Phoenix, AZ/US, ³Denver, CO/US, ⁴Hershey, PA/US, ⁵Barcelona, ES, ⁶Indianapolis, IN/US, ⁷Madrid, ES, ⁸Portland, OR/US, ⁹New York, NY/US, ¹⁰Kansas City, KS/US, ¹¹San Antonio, TX/US, ¹²Basking Ridge, NJ/US, ¹³Tarrytown, NY/US, ¹⁴Tarrytown, US
- 12:30 - 12:30 **74P - Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)**
H. Babiker¹, I. Brana², D. Mahadevan³, T. Owonikoko⁴, E. Calvo⁵, D. Rischin⁶, V. Moreno⁵, K. Papadopoulos⁷, M. Crittenden⁸, S. Formenti⁹, J. Giralt², P. Garrido⁵, A. Hervás Morón⁵, K. Mohan¹⁰, M. Fury¹⁰, I. Lowy¹¹, E. Stankevich¹², M. Feng¹², J. Li¹², M. Mathias¹⁰; ¹Tucson, US, ²Barcelona, ES, ³Memphis, TN/US, ⁴Atlanta, GA/US, ⁵Madrid, ES, ⁶Melbourne, VIC/AU, ⁷San Antonio, TX/US, ⁸Portland, OR/US, ⁹New York, NY/US, ¹⁰Tarrytown, NY/US, ¹¹Tarrytown, US, ¹²Basking Ridge, NJ/US
- 12:30 - 12:30 **75P - Cemiplimab, a human PD-1 monoclonal antibody, in patients (pts) with recurrent or metastatic cervical cancer: Interim data from phase I cohorts**
D. Rischin¹, M. Gil-Martin², A. González-Martin³, I. Brana², J. Hou⁴, D. Cho⁴, G. Falchook⁵, S. Formenti⁴, S. Jabbour⁶, K. Moore⁷, A. Naing⁸, K. Papadopoulos⁹, J. Baranda¹⁰, A. Weise¹¹, M. Fury¹², M. Feng¹³, J. Li¹³, I. Lowy¹⁴, M. Mathias¹²; ¹Melbourne, AU, ²Barcelona, ES, ³Madrid, ES, ⁴New York, NY/US, ⁵Denver, CO/US, ⁶New Brunswick, NJ/US, ⁷Oklahoma City, OK/US, ⁸Houston, TX/US, ⁹San Antonio, TX/US, ¹⁰Fairway, KS/US, ¹¹Detroit, MI/US, ¹²Tarrytown, NY/US, ¹³Basking Ridge, NJ/US, ¹⁴Tarrytown, US
- 12:30 - 12:30 **76P - Tislelizumab, an anti-PD-1 antibody, in patients with urothelial carcinoma (UC): Results from an ongoing phase I/II study**
S. Sandhu¹, A. Hill², H. Gan³, M. Friedlander⁴, M. Voskoboynik¹, P. Barlow⁵, A. Townsend⁶, J. Song⁷, Y. Zhang⁷, L. Liang⁸, J. Desai¹; ¹Melbourne, VIC/AU, ²Southport, QLD/AU, ³Heidelberg, AU, ⁴Randwick, NSW/AU, ⁵Auckland, NZ, ⁶Woodville South, SA/AU, ⁷San Mateo, CA/US, ⁸Beijing, CN
- 12:30 - 12:30 **77P - Preliminary results from a phase 1 study of AB122, a programmed cell death-1 (PD-1) inhibitor, in patients with advanced solid malignancies**
L. Seitz¹, A. Rieger², W. Berry³, D. Ashok³, D. Drenth³, L. Jin³, S. Lee³, A. Park³, D. Piovesan³, J. Tan³, M. Walters³, J. Karakunnel¹; ¹Hayward, US, ²Gaithersburg, US, ³Hayward, CA/US
- 12:30 - 12:30 **78P - Novel CTLA4 antibodies demonstrate potent anti-tumor activity in humanized CTLA4 mouse model**
C. Guo¹, Y. Yang¹, Y. Guo², Y. Shen², J. Ni¹; ¹Beijing, CN, ²Beijing, CN

- 12:30 - 12:30 **79P - Avelumab in European patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from an ad hoc expanded access program (EAP)**
P. Ascierto¹, P. Nathan², V. Kasturi³, L. Dirix⁴, E. Fenig⁵, M. Hennesy⁶, J. Reed⁶, A. Engelsberg⁷, S. Hariharan⁸, C. Lebbe⁹; ¹Napoli, IT, ²Northwood, Middlesex/GB, ³Rockland, US, ⁴Wilrijk, BE, ⁵Petah Tikva, IL, ⁶Billerica, MA/US, ⁷Berlin, DE, ⁸New York, NY/US, ⁹Paris, CEDEX 10/FR
- 12:30 - 12:30 **80P - Anti-GITR agonist TRX518 in combination with gemcitabine in advanced solid cancers: Preliminary safety and efficacy from a multi-center phase Ib trial**
V. Velcheti¹, T. Bauer², J. Luke³, O. Rixe⁴, D. Bajor⁵, G.S. Naik⁶, C. Sirard⁷, D. Davar⁸; ¹New York, NY/US, ²Nashville, US, ³Chicago, IL/US, ⁴Albuquerque, NM/US, ⁵Cleveland, OH/US, ⁶Cambridge, US, ⁷Cambridge, MA/US, ⁸Pittsburgh, PA/US
- 12:30 - 12:30 **81P - Optimizing novel anti-4-1BB antibodies on a in vivo drug screening platform**
Y. Yang¹, Y. Guo², Y. Shen², J. Ni¹; ¹Beijing, CN, ²Beijing, CN
- 12:30 - 12:30 **82P - Human PD-1/OX40 double knock-in mouse, a novel model for evaluating in vivo efficacy of the combination therapy of immune-oncology drugs**
T. Gan¹, Y. Li², Y. Shen¹, Y. Guo¹; ¹Beijing, CN, ²Wakefield, MA/US
- 12:30 - 12:30 **83P - Optimising TNFRSF agonism and checkpoint blockade with a novel CD137/PD-L1 bispecific antibody**
M. Lakins, J. Munoz-Olaya, D. Jones, R. Giambalvo, C. Hall, A. Knudsen, N. Masque Soler, S. Pechouckova, E. Goodman, C. Gradinaru, A. Koers, S. Marshall, M. Wydro, F. Wollerton, S. Batey, D. Gliddon, M. Davies, M. Morrow, M. Tuna, N. Brewis; Cambridge, GB
- 12:30 - 12:30 **84P - Safety and clinical outcome in patients with microsatellite-stable, metastatic colorectal or pancreatic cancer treated with the CXCL12 inhibitor NOX-A12 in combination with PD-1 checkpoint inhibitor pembrolizumab**
N. Halama¹, U. Prüfer¹, A. Frömmering², D. Beyer², D. Eulberg², J. Jungnelius², A. Mangasarian²; ¹Heidelberg, DE, ²Berlin, DE
- 12:30 - 12:30 **85P - Evaluation of the safety and the tolerability of durvalumab plus tremelimumab combined with FOLFOX in metastatic colorectal cancer (MEDITREME)**
J.-D. Fumet¹, N. Isambert², A. Hervieu¹, S. Zanetta², J.-F. Guion¹, A. Hennequin¹, E. Rederstorff¹, A. Bertaut¹, F. Ghiringhelli²; ¹Dijon, FR, ²Dijon, Cedex/FR
- 12:30 - 12:30 **86P - Cabozantinib in combination with anti-PD1 immune checkpoint inhibitor in syngeneic tumor mouse models**
S. Rolland¹, S. Klinz², F. Meyer-Losic¹, J. Nahkle¹, R. Delille¹, M. Hillairet de Boisferon³; ¹Les Ulis, FR, ²Cambridge, US, ³Dijon Cedex, FR

- 12:30 - 12:30 **87P - New clinical data from the DeCide1 trial: Results on DPX-Survivac, low dose cyclophosphamide (CPA), and epacadostat (INCB024360) in subjects with advanced recurrent epithelial ovarian cancer**
O. Dorigo¹, A. Oza², J. Tanyi³, J. Strauss⁴, T. Pejovic⁵, S. Ghamande⁶, P. Ghatage⁷, J. Villella⁸, S. Fiset⁹, L. MacDonald⁹, H. Torrey¹⁰, G. Weir¹⁰, O. Hrytsenko¹⁰, M. Stanford¹⁰, R. Newton¹¹, L. Leopold¹², G. Rosu⁹; ¹Palo Alto, AL/US, ²Toronto, Ontario/CA, ³Philadelphia, PA/US, ⁴Dallas, TX/US, ⁵Portland, OR/US, ⁶Augusta, GA/US, ⁷Calgary, CA, ⁸New York, NY/US, ⁹Halifax, CA, ¹⁰Dartmouth, NS/CA, ¹¹Wilmington, DE/US, ¹²Wilmington, US
- 12:30 - 12:30 **88P - Run-in-phase results from a multicenter phase II trial to evaluate pembrolizumab (P) and gemcitabine (Gem) in patients (pts) with HER2-negative advanced breast cancer (ABC): GEICAM/2015-04 PANGEA-Breast**
V. Quiroga¹, E. Holgado¹, J.L. Alonso², R. Andres³, F. Moreno Anton¹, M.D.C. Alamo De La Gala⁴, F. Henao⁴, B. Cirauqui Cirauqui⁵, M. Margeli⁶, J. Cortes Castan⁷, M. Gion Cortes¹, A. Soto², S. Benito¹, M.J. Escudero⁸, M. Chiesa⁸, R. Caballero⁹, S. Bezares Montes⁹, E. Carrasco⁸, L. De La Cruz Merino⁴; ¹Madrid, ES, ²Murcia, ES, ³Zaragoza, ES, ⁴Sevilla, ES, ⁵Badalona, Barcelona/ES, ⁶Badalona, ES, ⁷Barcelona, ES, ⁸San Sebastian De Los Reyes, ES, ⁹San Sebastian De Los Reyes, Madrid/ES
- 12:30 - 12:30 **89P - Pre-clinical evaluation of bifunctional SIRP α -antibody fusion proteins for the treatment of acute myeloid leukemia**
L. Pascual Ponce, C. Heitmüller, J.-H. Kozik, M. Subklewe, N.C. Fenn, K.-P. Hopfner; Munich, DE
- 12:30 - 12:30 **90P - Immunosuppressive mechanisms in acute myeloid leukemia with mutated nucleophosmin**
K. Kuželová, B. Brodská, P. Otevřelová, C. Šálek; Prague, CZ
- 12:30 - 12:30 **91P - A dual-targeting fusion protein, human PVR-4-1BBL for immunotherapy in AML**
H.-Y. Park¹, H. Nam², H. Kwon², C. Yu², S. Song², I. Oh², H. Yang², E.-C. Jo², J. Won², S.-Y. Eun²; ¹Gyeonggi, KR, ²Youngin-Si, KR
- 12:30 - 12:30 **92P - Understanding the anti-tumor T cell responses modulation mediated by chemoradiation to improve immunotherapy efficacy**
E. Lauret¹, C. Bonin¹, L. Rangan¹, L. Boullerot², J. Boustani¹, C. Fagnoni-Legat¹, S. Perrin¹, C. Mirjolet³, M. Dosset¹, R. Boidot³, S. Servagi⁴, B. De Bari¹, O. Adotevi⁵; ¹Besançon, FR, ²Besançon, FR, ³Dijon, FR, ⁴Reims, FR, ⁵Besançon, CEDEX/FR
- 12:30 - 12:30 **93P - Anti-tumor effects of a small molecule C-C chemokine receptor 4 inhibitor in mouse tumor models**
C. Li¹, J. Campbell², L. Ertl³, Z. Miao¹, V. Chhina¹, A. Kumamoto¹, S. Yau³, T. Dang³, P. Zhang³, T. Schall³, R. Singh³; ¹Mountain View, US, ²Mountain View, Ca, US, ³Mountain View, CA/US

- 12:30 - 12:30 **94P - Increased antitumour activity and extravasation of immune checkpoint inhibitor due to hyaluronidase expressed from oncolytic adenovirus VCN-01 and generation of new viruses with improved hyaluronidase activity**
M. Farrera¹, A. Mato-Berciano¹, S. Morgado¹, R. Moreno², J. de Sostoa Pomes², R. Alemany², M. Bazan-Peregrino¹; ¹Sant Cugat Del Valles, ES, ²Barcelona, ES
- 12:30 - 12:30 **95P - Targeting the tumor stroma with a bispecific T-cell engager-armed oncolytic adenovirus**
J. de Sostoa Pomés¹, C. Fajardo¹, R. Moreno², M. D. Ramon¹, M. Farrera Sal², R. Alemany²; ¹Hospitalet De Llobregat, ES, ²Barcelona, ES
- 12:30 - 12:30 **96P - Preliminary pharmacokinetic results from a phase I study of GBR 1302 in patients with HER2 positive cancers**
G. Gudi¹, V. Ca², S. Gn², C. von Gunten³, E. Fluhler⁴, J. Back³; ¹Mahwah, US, ²Mumbai, IN, ³La Chaux-De-fonds, CH, ⁴Paramus, AL/US
- 12:30 - 12:30 **97P - Circulating RNAs in advanced colorectal cancer patients reveal increased expression of PD-1 with conventional CRC therapy**
M. Nasrullah¹, M.A. Bakhrebah², M.A. Hassan¹, A. Alghamdi¹, W.H. Abdulaal¹, M.A. Zamzami¹, A.A.-G. Ghafari¹, M.I. Khan¹, H. Choudhry¹; ¹Jeddah, SA, ²Riyadh, SA
- 12:30 - 12:30 **98P - Standardized and compliant bio-informatics pipeline for neoepitope analysis in oncology clinical trials**
N. Masloboeva-Siwach¹, S. Ribí¹, H. Lempiäinen¹, T. Rujan¹, M. Flesch²; ¹Basel, CH, ²Munich, DE
- 12:30 - 12:30 **99P - Harnessing copper in cancer to enhance anti-tumor immune response**
F. Voli¹, L. Lerra¹, K. Kimpton², F. Saletta³, G. Cirillo⁴, M. Kavallaris¹, O. Vittorio²; ¹Sydney, AU, ²Sydney, NSW/AU, ³Nsw, ACT/AU, ⁴Rende (cs), IT
- 12:30 - 12:30 **100P - Balancing the efficacy and toxicity of anti-CD47 antibodies by direct screening in humanized mouse models**
Y. Li¹, T. Gan², Y. Guo², Y. Shen², Y. Yang³, J. Ni³; ¹Wakefield, MA/US, ²Beijing, CN, ³Beijing, CN
- 12:30 - 12:30 **101P - First evidence of antitumor activity of ITPP, a novel hypoxia-modifier: Results of a phase Ib trial**
M. Schneider¹, P. Limani¹, M. Linecker¹, P. Kron¹, H. Petrosky¹, B. Pestalozzi², A. Jetter¹, R. Graf¹, B. Humar¹, J.-M. Lehn³, P.-A. Clavien¹; ¹Zurich, CH, ²Zürich, CH, ³Strasbourg, FR
- 12:30 - 12:30 **102P - Targeting human CD141+ DC using CLEC9A antibodies for cancer immunotherapy**
K.-A. Masterman¹, F. Pearson², K. Tullett³, O. Haigh⁴, C. Walpole⁴, G. Daraj⁴, M. Lahoud³, I. Leal Rojas⁴, K. Radford²; ¹Brisbane, AU, ²Woolloongabba, AU, ³Clayton, ACT/AU, ⁴Woolloongabba, QLD/AU

- 12:30 - 12:30 **103P - Enhancing NY-ESO-1 antigen expression in lung cancer cells through gene hypomethylation using 5-Aza-2'-deoxycytidine**
S. Dermime, V. Inchakalody, V. Nair, A. El-Ashi, S. Taleb, Q. Fernandes, L. Al-Zaidan, A. Iskandarani, S. Sivaraman, F. Sahir, R. Krishnankutty, L. Therachiyil, M. Merhi, A. Raza, S. Uddin, E. Elkord, A. Knuth; Doha, QA
- 12:30 - 12:30 **104P - PIG-C and SOCS3: Potential immunotargets regulated by non-coding RNAs in TNBC**
M. Armanios, R. Abdel Tawab, H. El Tayebi; Cairo, EG
- 12:30 - 12:30 **105P - The impact of HIPEC on the anticancer immune response**
L. Roth, E. Breuer, A. Gupta, R. Graf, P.-A. Clavien, K. Lehmann; Zurich, CH
- 12:30 - 12:30 **106P - Oncolysis dominated therapeutic effect of LCMV-GP pseudotyped vesicular stomatitis virus in a syngeneic lung cancer model**
G. Wollmann¹, L.-M. Schreiber¹, C. Urbiola¹, K. Das¹, B. Spiesschaert¹, J. Kimpel¹, F. Heinemann², B. Stierstorfer², P. Müller², M. Petersson¹, P. Erlmann¹, D. von Laer¹; ¹Innsbruck, AT, ²Biberach A.d. Riss, DE
- 12:30 - 12:30 **107TiP - Phase I safety and pharmacokinetics of ADU-1604, an anti-CTLA-4 antibody, in adults with metastatic melanoma**
M. Hendriks, E. de Cock, K. Maplestone, H. Namini, A. van Elsas; Oss, NL
- 12:30 - 12:30 **108TiP - EMPOWER-lung 1: A randomized, open-label, multi-national, phase III trial of cemiplimab, a human PD-1 monoclonal antibody, versus chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1**
V. Sriuranpong¹, O. Altundag², P. Clingan³, N. Rizvi⁴, O. Aren Frontera⁵, A. Sezer⁶, S. Paydas⁶, M. Shavdia⁷, I. Bondarenko⁸, O. Gladkov⁹, S. Lee¹⁰, S. Li¹¹, P. Snodgrass¹², P. Rietschel¹³; ¹Bangkok, TH, ²Ankara, TR, ³Wollongong, NSW/AU, ⁴New York, NY/US, ⁵Santiago, CL, ⁶Adana, TR, ⁷Tbilisi, GE, ⁸Dnipropetrovsk, UA, ⁹Chelyabinsk, RU, ¹⁰Tarrytown, AL/US, ¹¹Basking Ridge, NJ/US, ¹²Tarrytown, US, ¹³Tarrytown, NY/US
- 12:30 - 12:30 **109TiP - AcS; immunotherapy trials: Anti-PD-1 therapy for adult patients with selected rare cancer types**
A. Marabelle¹, S. Chevret², F. Janot¹, B. Escudier³, D. Pouessel⁴, C. Tournigand⁵, K. Hoang-Xuan⁶, L. Mortier⁷, B. Rousseau⁵, M. Schlumberger³, I. Ray-Coquard⁸, J.-Y. Blay⁸, P. Niccoli⁹, A. Jaccard¹⁰, D. Couch², N. Hoog-Labouret¹¹, I. Pauporte², C. Massard³; ¹Villejuif, FR, ²Paris, FR, ³Villejuif, CEDEX/FR, ⁴Toulouse, FR, ⁵Créteil, CEDEX/FR, ⁶Paris, CEDEX 13/FR, ⁷Lille, CEDEX/FR, ⁸Lyon, CEDEX/FR, ⁹Marseille, FR, ¹⁰Limoges, FR, ¹¹Boulogne-Billancourt, FR
- 12:30 - 12:30 **110TiP - A phase I dose escalation trial evaluating the impact of an in situ immunization strategy with intra-tumoral injections of Pexa-Vec in combination with ipilimumab in advanced solid tumors with injectable lesions**

A. Marabelle¹, L. Eberst², C. Terret³, F. Pilleul⁴, C. Mastier⁵, A. Bouhamama⁴, L. Gilles-Afchain⁴, S. Laurent⁴, I. Delzano⁴, C. Reynaud⁴, C. Caux⁴, C. Caux⁴, G. Garin⁴, A.-S. Bidaux⁴, D. Perol³, N. Stojkowitz⁶, M. Homerin⁷, H. Leenders⁷, P. Cassier⁴; ¹Villejuif, FR, ²Lyon, Cedex 08/FR, ³Lyon, CEDEX/FR, ⁴Lyon, FR, ⁵Suresnes, FR, ⁶Illkirch-Graffenstaden, FR, ⁷Paris, FR

| | | |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------|---------------|
| 13:00 - 14:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium 1 | Room C |
| 14:15 - 15:45 | Type: Educational session Title: What's new in chest tumours Chair(s): Rolf A. Stahel, CH; Solange Peters, CH | Room A |

- 14:15 - 14:35 **Chemotherapy combos in NSCLC**
E. Smit, Amsterdam, NL
- 14:35 - 14:55 **Immunotherapy combos in NSCLC**
S. Peters, Lausanne, CH
- 14:55 - 15:15 **Immunotherapy in locally advanced NSCLC**
E. Felip, Barcelona, ES
- 15:15 - 15:35 **The role of immunotherapy in mesothelioma**
J. Aerts, Rotterdam, Noord Brabant/NL
- 15:35 - 15:45 **General discussion / Q&A**

| | | |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| 14:15 - 15:45 | Type: Educational session Title: What's new in melanoma & Merkel cell carcinoma (MCC) Chair(s): Reinhard Dummer, CH; John Haanen, NL | Room C |
| 14:15 - 14:35 | Update on adjuvant therapy in advanced melanoma <u>R. Dummer</u> , Zurich, CH | |
| 14:35 - 14:55 | Progress in biology and therapy of Merkel cell carcinoma <u>J. Becker</u> , Essen, DE | |
| 14:55 - 15:15 | Early development programs in advanced melanoma <u>O. Michielin</u> , Lausanne, CH | |
| 15:15 - 15:35 | Adoptive cell therapy in melanoma <u>J. Haanen</u> , Amsterdam, NL | |
| 15:35 - 15:45 | General discussion / Q&A | |
| 15:45 - 16:15 | Type: Break Title: Coffee break | Foyer |
| 16:15 - 17:45 | Type: Educational session Title: Intratumoural immunotherapy Chair(s): Aurelien Marabelle, FR; Kevin Harrington, GB | Room A |
| 16:15 - 16:35 | Rationale for intratumoural immunotherapy <u>A. Marabelle</u> , Villejuif, FR | |
| 16:35 - 16:55 | Cryoablation and immunotherapy <u>R. Duran</u> , Lausanne, CH | |
| 16:55 - 17:15 | Intratumoural pattern recognition receptor agonists <u>K. Harrington</u> , London, GB | |
| 17:15 - 17:35 | Oncolytic virus platforms <u>R. Alemany</u> , Barcelona, ES | |
| 17:35 - 17:45 | General discussion / Q&A | |

| | | |
|----------------------|-----------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| 16:15 - 17:45 | Type: Educational session Title: Imaging and nuclear medicine Chair(s): E.G. Elisabeth de Vries, NL; Niklaus Schaefer, CH | Room C |
| 16:15 - 16:35 | Preclinical and clinical imaging of macrophages <u>M. Keyaerts</u> , Brussels, BE | |
| 16:35 - 16:55 | ImmunoPET detection of CD8 cytotoxic lymphocytes in immunotherapy <u>A. Wu</u> , Los Angeles, US | |
| 16:55 - 17:15 | Visualising CTL effector function and immunotherapy by intravital microscopy <u>P. Friedl</u> , Nijmegen, NL | |
| 17:15 - 17:35 | Immune checkpoint inhibitors <u>E.G.E. de Vries</u> , Groningen, NL | |
| 17:35 - 17:45 | General discussion / Q&A | |
| 18:15 - 19:15 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium 2 | Room C |

15.12.2018

08:00 - 09:00 Type: Mini Oral session **Room A**
Title: Mini Oral session

Chair(s): George Coukos, CH; John Haanen, NL; Solange Peters, CH; Thomas Powles, GB

- 08:00 - 08:05 **LBA2 - Proton pump inhibitors negatively impact survival of PD-1 inhibitor based therapies in metastatic melanoma patients**
K. Homicsko¹, G. Richtig², F. Tuchmann², Z. Tsourti³, D. Hanahan⁴, G. Coukos⁵, M. Wind-Rotolo⁶, E. Richtig⁷, P. Zygoura³, C. Holler², U. Dafni⁸, O. Michielin⁴; ¹Lausanne, Vaud/CH, ²Vienna, AT, ³Athens, GR, ⁴Lausanne, CH, ⁵Epalinges, CH, ⁶New York, NY/US, ⁷Graz, AT, ⁸Athens, Attica/GR
- 08:05 - 08:10 **LBA3 - 30 months relapse-free survival, overall survival, and long-term toxicity update of (neo)adjuvant ipilimumab (ipi) + nivolumab (nivo) in macroscopic stage III melanoma (OPACIN trial)**
E. Rozeman, K. Sikorska, B. van de Wiel, L. Fanchi, O. Krijgsman, H. van Thienen, L. Pronk, A. Broeks, L. Grijpink-Ongering, S. Ter Meulen, A. Bruining, W. Klop, H. van Tinteren, D. Peeper, J. Haanen, A. van Akkooi, T. Schumacher, C. Blank; Amsterdam, NL
- 08:10 - 08:15 **340 - Efficacy and safety of tabellecleucel in patients with EpsteinBarr Virus-associated leiomyosarcomas (EBV+ LMS)**
L. Kurlander¹, A. Srinivasan², A. Ghobadi³, S. Suser¹, E. Doubrovina¹, F. Boulad¹, L. Mascarenhas⁴, M. Laquaglia¹, A. Price¹, G. Behr¹, B. Shulkin², A. Sudhindra⁵, Y. Wei⁵, M. Hiremath⁵, W. Navarro⁵, R. O'Reilly¹, S. Prockop¹; ¹New York, NY/US, ²Memphis, TN/US, ³St Louis, MO/US, ⁴Los Angeles, CA/US, ⁵South San Francisco, CA/US
- 08:15 - 08:20 **10 - Advanced CT imaging features reflect distinct tissue immune profiles and exhibit high prognostic impact on NSCLC**
G. Mazzaschi¹, P. Pagano¹, G. Milanese¹, D. Madeddu¹, A. Falco¹, G. Armani¹, G. Bocchialini², D. Marturano¹, L. Ampollini¹, B. Lorusso¹, C. Lagrasta¹, N. Sverzellati¹, M. Silva¹, M. Tiseo¹, F. Quaini¹, G. Roti¹; ¹Parma, IT, ²Parma, Parma/PR/IT
- 08:20 - 08:25 **330 - Anti-MUC1 CAR-T cells combined with PD-1 knockout engineered T cells for patients with non-small cell lung cancer (NSCLC): A pilot study**
S. Chen¹, Y. Lin², S. Zhong¹, H. An¹, Y. Lu¹, M. Yin¹, W. Liang¹, E. McGowan³; ¹Guangzhou, CN, ²Sydney, AU, ³Sydney, ACT/AU
- 08:25 - 08:30 **510 - First-line pembrolizumab monotherapy in metastatic PD-L1 positive non-small cell lung cancer: A real-world analysis of time on treatment in US community oncology practices**
V. Velcheti¹, S. Chandwani², X. Chen³, M.C. Pietanza⁴, T. Burke⁵; ¹New York, NY/US, ²Lebanon, US, ³Kenilworth, US, ⁴Rahway, NJ/US, ⁵Rahway, US
- 08:30 - 08:35 **700 - A phase Ia/Ib trial of tislelizumab, an anti-PD-1 antibody (ab), in patients (pts) with advanced solid tumors**

S. Deva¹, J.-S. Lee², C.-C. Lin³, C.-J. Yen⁴, M. Millward⁵, Y. Chao³, B. Keam⁶, M. Jameson⁷, M.-M. Hou⁸, Y.-K. Kang⁶, B. Markman⁹, C.-H. Lu¹⁰, K.-M. Rau¹¹, K.-H. Lee⁶, L. Horvath¹², M. Friedlander¹³, A. Hill¹⁴, J. Wu¹⁵, J. Hou¹⁵, J. Desai⁹; ¹Auckland, NZ, ²Seongnam-Si, Gyeonggi-do, KR, ³Taipei, TW, ⁴Taiman City, TW, ⁵Nedlands, WA/AU, ⁶Seoul, KR, ⁷Hamilton, NZ, ⁸Linkou, TW, ⁹Melbourne, VIC/AU, ¹⁰Chia-Yi, TW, ¹¹Kaohsiung, TW, ¹²Camperdown, NSW/AU, ¹³Randwick, NSW/AU, ¹⁴Southport, QLD/AU, ¹⁵San Mateo, CA/US

08:35 - 08:40 **20 - Somatic mutations in BRCA2, NFE2L2, ARID1A and NOTCH1 sensitize to anti-PDL1 therapy in multiple tumor types**

M. Kuziora¹, H. Si², B. Higgs³, P. Brohawn¹, K. Streicher¹, M. Jure-Kunkel², R. Raja², E. Helman⁴, A. Franovic⁴, Z. Cooper², Y. Shrestha³, N. Holoweckyj², Y. Lee², I. Achour², J. Ye², P. Mukhopadhyay³, P. Dennis⁵, G. Melillo⁶, S. Abdullah⁷, K. Ranade²; ¹Gaithersburg, AL/US, ²Gaithersburg, MD/US, ³Gaithersburg, US, ⁴Redwood City, US, ⁵New York, MD/US, ⁶Gaithersburg, Maryland/US, ⁷Gaithersburg, NY/US

08:40 - 09:00 **Discussion led by Moderators**

09:10 - 10:40 **Type: Educational session** **Room A**
Title: Immuno-oncology: State of the art I
Chair(s): Aurelien Marabelle, FR; John Haanen, NL

09:10 - 09:30 **Arginase inhibition to modulate the TME: Rationale and early clinical experience**
S. Ioannidis, Epalinges, Not Applicable/CH

09:30 - 09:50 **When 1+1 = 3: Unlocking the potential of the IL-2 pathway with NKTR-214 in combination treatment**
J. Zalevsky, San Francisco, US

09:50 - 10:10 **Directing the immune system with neoantigen therapeutics**
R. Gaynor, Cambridge, Indianapolis/US

10:10 - 10:30 **ImmTACTM Platform: Novel bispecific high affinity TCR-effector fusions to modulate the immune system for the treatment of cancer**
L. Humbert, Abingdon, GB

10:30 - 10:40 **General discussion / Q&A**

09:10 - 10:40 **Type: Educational session** **Room C**
Title: What's new in genitourinary (GU) tumours
Chair(s): Laurence Albiges, FR; Thomas Powles, GB

09:10 - 09:30 **Biomarkers for immune therapy in urology cancer: Fact or fiction**
T. Powles, London, GB

09:30 - 09:50 **Immune therapy for non-muscle invasive and muscle invasive bladder cancer**
A. Necchi, Milan, IT

09:50 - 10:10 **Novel immune combinations for genitourinary cancers**
C. Drake, Baltimore, MD/US

10:10 - 10:30 **Firstline immune therapy in clear cell renal cancer**
L. Albiges, Villejuif, FR

10:30 - 10:40 **General discussion / Q&A**

10:40 - 11:00 **Type: Break** **Foyer**
Title: Coffee break

11:00 - 12:30 **Type: Educational session** **Room A**
Title: Cancer neoantigens
Chair(s): George Coukos, CH; Sine Reker Hadrup, DK

11:00 - 11:20 **Immunogenicity of neoepitopes**
D. Chowell, New York, US

11:20 - 11:40 **MS approaches to neoantigen identification for immunotherapy**
M. Bassani-Sternberg, Lausanne, CH/CH

11:40 - 12:00 **Phenotype markers to identify tumor reactive (neoantigen specific) T cells**
A. Gros, Barcelona, ES

12:00 - 12:20 **The role of neo and shared antigens in immunotherapy**
S. Reker Hadrup, Frederiksberg, DK

12:20 - 12:30 **General discussion / Q&A**

| | | |
|----------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| 11:00 - 12:30 | Type: Proffered Paper session Title: Proffered Paper session III Chair(s): John Haanen, NL; Solange Peters, CH | Room C |
| 11:00 - 11:15 | LBA1 - Fast progression in patients treated with a checkpoint inhibitor (cpi) vs chemotherapy in OAK, a phase III trial of atezolizumab (atezo) vs docetaxel (doc) in 2L&#x0002B; NSCLC <u>D. Gandara</u> ¹ , M. Reck ² , S. Morris ³ , A. Cardona ³ , D. Mendus ⁴ , M. Ballinger ⁴ , A. Rittmeyer ⁵ ; ¹ Sacramento, CA/US, ² Grosshansdorf, DE, ³ Basel, CH, ⁴ South San Francisco, CA/US, ⁵ Immenhausen, DE | |
| 11:15 - 11:30 | 500 - Effects of antibiotics and proton pump inhibitors in NSCLC patients treated with atezolizumab and docetaxel: Pooled analysis of the OAK and POPLAR trials <u>M. Chalabi</u> ¹ , A. Cardona ² , D. Nagarkar ³ , A.M. Dhawahir Scala ² , M. Albert ⁴ , M. Kok ¹ , T. Powles ⁵ , F. Herrera ⁶ ; ¹ Amsterdam, NL, ² Basel, CH, ³ South San Francisco, US, ⁴ South San Francisco, California/US, ⁵ London, GB, ⁶ Lausanne, CH | |
| 11:30 - 11:45 | Invited Discussant LBA1 and 500 <u>J. Haanen</u> , Amsterdam, NL | |
| 11:45 - 12:00 | LBA4 - Long-term follow-up in the KEYNOTE-010 study of pembrolizumab (pembro) for advanced NSCLC, including in patients (pts) who completed 2 years of pembro and pts who received a second course of pembro <u>R.S. Herbst</u> ¹ , E. Garon ² , D.-W. Kim ³ , B. Chul Cho ³ , J.L. Pérez Gracia ⁴ , J.-Y. Han ⁵ , C. Dubos Arvis ⁶ , M. Majem ⁷ , M. Forster ⁸ , I. Monnet ⁹ , S. Novello ¹⁰ , Z. Szalai ¹¹ , M. Gubens ¹² , W.-C. Su ¹³ , G. Ceresoli ¹⁴ , A. Samkari ¹⁵ , E. Jensen ¹⁵ , G. Lubiniecki ¹⁵ , P. Baas ¹⁶ ; ¹ New Haven, US, ² Santa Monica, CA/US, ³ Seoul, KR, ⁴ Pamplona, ES, ⁵ Goyang-Si, KR, ⁶ Caen, FR, ⁷ Barcelona, ES, ⁸ London, GB, ⁹ Créteil, FR, ¹⁰ Orbassano, IT, ¹¹ Gyor, HU, ¹² San Francisco, CA/US, ¹³ Tainan, TW, ¹⁴ Bergamo, IT, ¹⁵ Kenilworth, NJ/US, ¹⁶ Amsterdam, NL | |
| 12:00 - 12:15 | 490 - IMpower133: Patient-reported outcomes (PROs) in a ph1/3 study of first-line (1L) atezolizumab (atezo) && <u>R. Califano</u> ¹ , A. Kazarnowicz ² , N. Karaseva ³ , A. Sánchez ⁴ , S. Liu ⁵ , L. Horn ⁶ , C. Quach ⁷ , W. Yu ⁷ , F. Kabbinavar ⁷ , S. Lam ⁷ , A. Mansfield ⁸ ; ¹ Manchester, GB, ² Olsztyn, PL, ³ St Petersburg, RU, ⁴ Seville, ES, ⁵ Washington Dc, MD/US, ⁶ Nashville, TN/US, ⁷ South San Francisco, CA/US, ⁸ Rochester, MN/US | |
| 12:15 - 12:30 | Invited Discussant LBA4 and 490 <u>S. Peters</u> , Lausanne, CH | |
| 12:30 - 13:00 | Type: Poster Display session Title: Poster Display session | Room B |
| 13:00 - 14:00 | Type: Industry Satellite Symposium Title: Industry Satellite Symposium 3 | Room C |

14:15 - 15:45 **Type: Educational session** **Room A**
Title: Modern anticancer vaccines
 Chair(s): Nora Disis, US; Anthony Chan, HK

14:15 - 14:35 **Vaccines to enhance CD4 T-helper responses to oncogenic proteins**
N. Disis, Seattle, US

14:35 - 14:55 **Neoantigen-based vaccine approaches**
M. Bassani-Sternberg, Lausanne, CH/CH

14:55 - 15:15 **Self and viral antigens-HPV vaccine for therapy**
M. Welters, Leiden, NL

15:15 - 15:35 **Prostate cancer vaccines**
L. Fong, San Francisco, CA/US

15:35 - 15:45 **General discussion / Q&A**

14:15 - 15:45 **Type: Educational session** **Room C**
Title: What's new in haematological malignancies
 Chair(s): Markus Manz, CH; Caroline Arber Barth, CH

14:15 - 14:35 **BiTE antibodies in hematological malignancies**
R.C. Bargou, Würzburg, DE

14:35 - 14:55 **Modifying GvHD and GvL post allo-HSCT**
R. Zeiser, Freiburg, DE

14:55 - 15:15 **Checkpoint inhibitors in haem-onc**
M. Manz, Zurich, CH

15:15 - 15:35 **CD47-SIRPa directed therapies in (hemato) oncology**
J.-P. Volkmer, Menlo Park, US

15:35 - 15:45 **General discussion / Q&A**

15:45 - 16:15 **Type: Break** **Foyer**
Title: Coffee break

16:15 - 17:45 **Type: Educational session** **Room A**
Title: What's new in breast & gynaecological cancers
 Chair(s): Nora Disis, US; Giuseppe Curigliano, IT

16:15 - 16:35 **The immune environment of ovarian cancer**
B. Nelson, Vancouver, CA

16:35 - 16:55 **Optimising immune checkpoint inhibitor therapy in ovarian cancer**
L. Kandalaft, Lausanne, CH

16:55 - 17:15 **Integrative analyses to identify genetic determinants of immune responsiveness in cancer**
D. Bedognetti, Didra, QA

17:15 - 17:35 **Defining the immunogram of breast cancer: Evidences from clinical trials**
G. Curigliano, Milan, IT

17:35 - 17:45 **General discussion / Q&A**

16:15 - 17:45 **Type: Educational session** **Room C**
Title: What's new in head and neck cancers
 Chair(s): Anthony Chan, HK; Neil Steven, GB

16:15 - 16:35 **Overview of recent developments in immunotherapy for H&N squamous cell cancer (HNSCC) and nasopharyngeal cancer (NPC)**
A. Chan, Shatin, HK

16:35 - 16:55 **How to mobilise innate immunity in H&N cancer**
C. Ottensmeier, Southampton, GB

16:55 - 17:15 **Opportunities to combine immune therapies and radiation**
E. Deutsch, Villejuif, CEDEX/FR

17:15 - 17:35 **Vaccine and EBV targeting IO strategies**
N. Steven, Birmingham, West Midlands/GB

17:35 - 17:45 **General discussion / Q&A**

16.12.2018

08:00 - 09:00 **Type: Panel Discussion** **Room C**
Title: Immuno-oncology endpoints for approval: The case of tumor agnostic approval for MSI-H cancers
 Chair(s): George Coukos, CH; Josep Tabernero, ES; Thomas Powles, GB

08:00 - 08:20 **The EMA position**
F. Pignatti, London, GB

08:20 - 09:00 **Discussion led by Chairs**

09:10 - 10:40 **Type: Educational session** **Room A**
Title: What's new in gastrointestinal (GI) cancers
 Chair(s): Niels Halama, DE; Bruno Sangro, ES

09:10 - 09:30 **Immune therapeutics in gastric and colorectal cancer**
J. Tabernero, Barcelona, ES

09:30 - 09:50 **Immunotherapy for HCC**
B. Sangro, Pamplona, ES

09:50 - 10:10 **A goal for immunotherapy in pancreatic cancer**
N. Halama, Heidelberg, DE

10:10 - 10:30 **Immune score and beyond**
J. Galon, Paris, FR

10:30 - 10:40 **General discussion / Q&A**

| | | |
|----------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------|
| 09:10 - 10:40 | Type: Educational session Title: Immuno-oncology: State of the art II Chair(s): Teresa Marafioti, GB; Alexandre Harari, CH | Room C |
| 09:10 - 09:30 | Spatially correlated high-plex protein (~ 100-plex) and high-plex mRNA (~ 1000-plex) profiling on FFPE tissue using Digital Spatial Profiling microscopy for immuno-oncology studies <u>J. Beechem</u> , Seattle, US | |
| 09:30 - 09:50 | Visual a new path forward: Simultaneously detect up to 37 protein markers all from a single scan with Imaging Mass Cytometry <u>R. Spada</u> , Les Ulis, FR | |
| 09:50 - 10:10 | TCR sequencing <u>H. Robins</u> , Seattle, US | |
| 10:10 - 10:30 | Phenoetics: Immuno-profiling and phenotyping of multiple immune cell subsets in situ in FFPE tissue sections <u>B. Wendik</u> , Rodgau, DE | |
| 10:30 - 10:40 | General discussion / Q&A | |
| 10:40 - 11:00 | Type: Break Title: Coffee break | Foyer |
| 11:00 - 12:30 | Type: Educational session Title: Beyond PD-1/PD-L1 axis blockade Chair(s): Bernard Fox, US; Keith Kerr, GB | Room A |
| 11:00 - 11:20 | Biomarker assessment for other I-O therapy (non-PD1) <u>K. Schalper</u> , New Haven, US | |
| 11:20 - 11:40 | Agonist immunomodulatory monoclonal antibodies <u>B. Fox</u> , Portland, US | |
| 11:40 - 12:00 | Immune checkpoint environment in haematological malignancies <u>T. Marafioti</u> , London, GB | |
| 12:00 - 12:20 | New checkpoints in the immunotherapy arena <u>P. Ascierto</u> , Napoli, IT | |
| 12:20 - 12:30 | General discussion / Q&A | |

11:00 - 12:30 **Type: Educational session** **Room C**
Title: What's new in brain tumours
Chair(s): Michael Weller, CH; Anna Sophie Berghoff, AT

11:00 - 11:20 **Immunosuppression in primary brain tumors**
M. Platten, Heidelberg, DE

11:20 - 11:40 **Checkpoint inhibition and CAR T cells for glioblastoma**
M. Weller, Zürich, CH

11:40 - 12:00 **Immunotherapy for metastatic brain cancer**
A.S. Berghoff, Vienna, AT

12:00 - 12:20 **Challenges in clinical trial design for patients with brain and leptomeningeal metastases**
E. Le Rhun, Lille, CEDEX/FR

12:20 - 12:30 **General discussion / Q&A**

12:30 - 13:00 **Type: Keynote Lecture** **Room A**
Title: Closing keynote lecture
Chair(s): George Coukos, CH; John Haanen, NL

12:30 - 12:50 **Reprogramming human T cell circuitry**
A. Marson, San Francisco, US